EnVVeno Medical Reveals Promising 2-Year Data From VenoValve Clinical Trial

enVVeno Medical (NVNO) reported positive interim two-year data from its VenoValve U.S. pivotal trial, demonstrating sustained clinical improvement in severe chronic venous insufficiency (CVI) in 42 subjects, with 83% showing meaningful benefit and 100% valve patency. Patients experienced an average 9.1-point improvement in rVCSS, a median 74% reduction in leg pain, and wound healing in 60% of ulcers, bolstering confidence in the VenoValve as a potential treatment for deep venous CVI ahead of the FDA's decision on its pre-market authorization application expected in the second half of 2025; NVNO is currently trading up 21.98%.

Analysis

enVVeno Medical Corp. (NVNO) has released compelling interim two-year follow-up data from its VenoValve U.S. pivotal trial, significantly bolstering the prospects for its first-in-class surgical replacement venous valve. The study, involving 42 subjects with severe chronic venous insufficiency (CVI), demonstrated sustained clinical efficacy: 83% of subjects maintained meaningful benefit (a 3-point or greater improvement in the revised Venous Clinical Severity Score, rVCSS), with an average rVCSS improvement of 9.1 points, a median 74% reduction in leg pain, and wound healing in 60% of ulcers. Crucially, 100% valve patency was maintained among subjects, underscoring the device's durability. This positive data, which prompted a 21.98% increase in NVNO's stock to $4.24 on the Nasdaq, substantially de-risks the clinical profile of VenoValve ahead of a pivotal FDA decision on its pre-market authorization (PMA) application, expected in the second half of 2025. The VenoValve targets deep venous CVI, a condition impacting millions with limited effective treatment options, positioning enVVeno for a significant market opportunity should FDA approval be granted.

Key Decisions for Investors

• The robust two-year pivotal trial data significantly de-risks VenoValve's pathway to market and strengthens the investment case for enVVeno Medical, particularly ahead of the anticipated H2 2025 FDA decision.
• Investors should closely monitor insights from the company's webcast discussing these results, further updates on the FDA review process for the pre-market authorization application, and any outlined pre-commercialization activities, as these will be key indicators of future performance.
• While the stock has reacted positively with a 21.98% gain, the primary valuation inflection point remains the FDA approval; a positive outcome could unlock substantial value given the large unmet medical need for effective CVI treatments.